Welcome to our dedicated page for IGM Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on IGM Biosciences stock.
IGM Biosciences, Inc. (Nasdaq: IGMS) is a clinical-stage biotechnology company dedicated to transforming the treatment landscape for cancer, infectious diseases, and autoimmune and inflammatory diseases. At the core of the company’s innovation is its proprietary IgM antibody technology platform, which is optimized for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines.
IGM Biosciences’ leading product candidate is IGM-2323, a bispecific IgM antibody currently in Phase 1 clinical trials aiming to treat patients with B cell non-Hodgkin lymphoma (NHL) and other B cell malignancies. Another promising candidate, IGM-8444, targets death receptor 5 (DR5) proteins and is being developed for the treatment of colorectal cancer. The company is also advancing IGM-7354, a bispecific IgM antibody designed to deliver interleukin-15 cytokines to PD-L1 expressing cells in patients with solid and hematologic malignancies.
IGM Biosciences has formed strategic collaborations to enhance its research and development efforts. These include partnerships with Atreca Inc. and BeiGene Ltd. to identify and develop novel IgM and IgA antibodies against SARS-CoV-2, and a strategic research collaboration with AbCellera to discover IgM antibodies. Additionally, IGM has an exclusive worldwide collaboration agreement with Sanofi to develop and commercialize IgM antibody agonists targeting oncology, immunology, and inflammation.
The financial outlook for IGM remains robust. For the 2023 fiscal year, the company projected operating expenses between $275 million and $285 million, including a non-cash stock-based compensation expense of around $50 million. IGM expects to end 2023 with over $325 million in cash and investments, ensuring its operations are funded into the second half of 2025.
Recent updates highlight significant progress in IGM’s pipeline. Notably, the company continues to advance candidates such as Imvotamab for severe systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
IGM’s commitment to innovation is demonstrated by its ongoing efforts to develop novel therapies that meet unmet medical needs. With a robust pipeline and strategic partnerships, IGM Biosciences aims to make significant strides in the biopharmaceutical industry.
IGM Biosciences announced promising Phase 1 data for IGM-8444 in metastatic colorectal cancer, demonstrating an encouraging safety profile when combined with FOLFIRI chemotherapy. The trial revealed multiple confirmed patient responses, with some patients achieving substantial tumor shrinkage. Median progression-free survival was reported at 5.5 months for certain patient cohorts. Following these results, a randomized trial in second-line patients is set to begin in Q1 2023, aiming to further evaluate the effectiveness of IGM-8444 alongside FOLFIRI and bevacizumab.
IGM Biosciences, a clinical-stage biotechnology company, announced that CEO Fred Schwarzer will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 5:15 p.m. PST in San Francisco. The event will be available via a live webcast on the company's website, with a replay accessible for 30 days.
The company focuses on developing IgM antibodies for treating cancer, infectious diseases, and autoimmune disorders, leveraging a collaboration with Sanofi to develop IgM antibody agonists.
IGM Biosciences presented promising preclinical data for IGM-2644 and IGM-2537 at the 2022 ASH Annual Meeting. Both bispecific IgM antibodies showed potential anti-tumor activity with favorable safety profiles. IGM-2644 demonstrated superior cytotoxicity against myeloma cells compared to traditional IgG antibodies and is set for a Phase 1 trial in early 2023. Similarly, IGM-2537 displayed potent activity against acute myeloid leukemia with minimal cytokine release, with IND filing anticipated in 2023. Biomarker data for imvotamab also indicated efficacy in low CD20 expressing tumors.
IGM Biosciences, a clinical-stage biotechnology company focused on IgM antibodies, announced that CEO Fred Schwarzer will participate in a virtual fireside chat at the Bank of America Biotech SMID Cap Conference on December 8, 2022, at 2:45 p.m. EST.
The event will be webcast live on the company’s website, with a replay available for 90 days. IGM is dedicated to developing innovative therapies for cancer and other diseases, leveraging its IgM antibody technology, which offers superior binding capabilities compared to traditional antibodies.
IGM Biosciences, a clinical-stage biotechnology firm focusing on IgM antibodies, announced that CEO Fred Schwarzer will participate in several investor conferences. The events include:
- Stifel Healthcare Conference on November 15 in New York
- Jefferies London Healthcare Conference on November 17 in London
- Evercore ISI HealthCONx Conference on December 1 (virtual)
Live webcasts will be available on the Company’s website and will remain archived for 90 days post-event.
IGM Biosciences (Nasdaq: IGMS) reported its Q3 2022 financial results, showing a net loss of $58 million, unchanged at $1.32 per share. Cash and investments rose to $469.1 million compared to $229.5 million at the end of 2021. Collaboration revenue reached $0.3 million, up from zero in Q3 2021. The company is progressing in its T cell engager portfolio, with promising data from the Phase 1 trial of imvotamab, where 7 of 8 complete response patients remain tumor-free after a year. IGM aims for a Phase 2 update on imvotamab in Q1 2023.
IGM Biosciences and ADC Therapeutics have partnered to evaluate a combination therapy for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). Their collaboration focuses on IGM's bispecific antibody, imvotamab, combined with ADC's ZYNLONTA®. A Phase 1 trial is expected to start in Q1 2023. Preliminary data shows imvotamab achieved a 50% complete response rate in prior studies, with manageable safety profile.
IGM Biosciences and ADC Therapeutics have formed a clinical trial collaboration to examine a combination therapy for relapsed/refractory B cell non-Hodgkin’s lymphoma (NHL). This partnership will evaluate IGM’s imvotamab, a bispecific antibody, alongside ADC’s ZYNLONTA®, an antibody-drug conjugate. The Phase 1 trial is slated to commence in Q1 2023. Previous data indicated a 50% complete response rate for imvotamab at optimal dosing, with manageable safety profiles. Both companies aim to address significant unmet medical needs in lymphoma treatments.
IGM Biosciences, a clinical-stage biotechnology company focused on IgM antibodies, has announced that CEO Fred Schwarzer will speak at three major investor conferences in New York. The conferences include the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, Baird 2022 Global Healthcare Conference on September 13, and H.C. Wainwright 24th Annual Global Investment Conference on September 14. Live webcasts will be available on the company's website, with replays archived for 90 days.
IGM Biosciences reported a net loss of $58.6 million, or $1.33 per share, for Q2 2022, compared to a $38.7 million loss in Q2 2021. The company received a $150 million upfront payment from Sanofi as part of a collaboration agreement to develop IgM antibodies. Cash and investments totaled $513.2 million at the end of Q2 2022. The firm continues advancing its clinical trials for imvotamab and IGM-8444, with initial safety updates expected soon. IGM anticipates filing IND applications for two new therapies this year and has projected 2022 cash reserves to be around $400 million.
FAQ
What is the current stock price of IGM Biosciences (IGMS)?
What is the market cap of IGM Biosciences (IGMS)?
What is IGM Biosciences, Inc.?
What are the key product candidates of IGM Biosciences?
What diseases is IGM Biosciences targeting?
Who are IGM Biosciences' strategic partners?
What financial outlook has IGM Biosciences projected for 2023?
What is IGM-2323?
What is the IgM antibody technology platform?
What is the significance of IGM Biosciences' collaboration with Sanofi?
What recent developments have been made in IGM's pipeline?
What are IGM Biosciences' recent financial achievements?
